GlassScriptPhysician profile
Brian Mark Melancon
NPI 1417526146
$4,934.91
in general payments reported to CMS, 2019-2025
39 companies · $763 in 2025
The $763 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $638 · 2022: $1,173 · 2023: $1,158 · 2024: $1,203 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $558.90 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.45 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $496.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $440.75 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $330.74 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $319.00 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $278.47 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Novartis Pharmaceuticals Corporation | $234.74 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.94 | 2021-2025 | Trintellix |
| Ibsa Pharma INC. | $196.21 | 2021-2024 | Tirosint, Licart, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.53 | 2021-2025 | Tradjenta, Synjardy, Jardiance |
| Lundbeck LLC | $116.77 | 2022-2024 | Rexulti |
| Amgen INC. | $109.57 | 2021-2025 | Repatha, Otezla, Prolia |
| Bausch Health US, LLC | $95.68 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.30 | 2022-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Melancon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.